Q4 2018 13F Holders as of 12/31/2018
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62.2M
-
Number of holders
-
62
-
Total 13F shares, excl. options
-
13.9M
-
Shares change
-
-1.23M
-
Total reported value, excl. options
-
$93.2M
-
Value change
-
-$9.55M
-
Number of buys
-
26
-
Number of sells
-
-38
-
Price
-
$6.73
Significant Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q4 2018
71 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 as of Q4 2018.
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) has 62 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13.9M shares
of 62.2M outstanding shares and own 22.29% of the company stock.
Largest 10 shareholders include FMR LLC (3.63M shares), FARALLON CAPITAL MANAGEMENT LLC (2.2M shares), BVF INC/IL (1.64M shares), GREAT POINT PARTNERS LLC (956K shares), MILLENNIUM MANAGEMENT LLC (690K shares), Vanguard Group Inc (660K shares), DIMENSIONAL FUND ADVISORS LP (490K shares), VHCP Management III, LLC (423K shares), RENAISSANCE TECHNOLOGIES LLC (340K shares), and BlackRock Inc. (261K shares).
This table shows the top 62 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.